Blood 2017-07-20
Eculizumab cessation in atypical hemolytic uremic syndrome.
Related Questions
Given the high cost of eculizumab, are there patient characteristics that inform which patients, if any, should be on indefinite therapy versus a time...
New answer by Medical Oncologist at Cedars-Sinai Medical Center (January 20, 2021)
I agree with all the points made by Dr. @Marshall A. Mazepa, but would add that genetic information can be useful in informing the discussion. Fakhouri et al recently publishe...